Snapshot from Sep 20, 2026 at 07:00 UTC. For live data and tracking: View Live
Business index inclusion

Insilico Medicine joins HKEX Tech 100

Analysis based on 6 articles · First reported Jul 20, 2026 · Last updated Sep 03, 2026

Sentiment
60
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The inclusion is expected to boost Insilico Medicine's stock liquidity and attract passive fund inflows, potentially supporting its share price. It also signals growing investor interest in AI-driven drug discovery, which may positively affect the broader biotech and AI sectors.

Biotechnology Pharmaceutical Artificial Intelligence

Insilico Medicine, a clinical-stage drug discovery company powered by generative AI, announced its inclusion in the HKEX Tech 100 Index. The inclusion follows methodology enhancements announced on 18 August 2026 to broaden exposure to emerging technology trends, including AI value chain opportunities. The changes will be implemented after market close on 11 September 2026 and take effect on 14 September 2026. The HKEX Tech 100 Index tracks 100 of the largest Hong Kong-listed companies with high exposure to key tech themes and is eligible for Southbound Stock Connect. For Insilico, inclusion validates its AI technology capabilities and is expected to enhance trading liquidity, expand capital access, and attract inflows from index-tracking passive funds and Mainland Chinese investors. The company has previously been included in several major index series, including MSCI Global Small Cap, Hang Seng Healthcare, Hang Seng Biotechnology, and FTSE Global indexes. Insilico recently reported total revenue of approximately $106 million in the first half of 2026, a 287% year-over-year increase, and achieved its first profitable half-year since listing with adjusted net profit exceeding $51 million. This milestone was driven by collaborations with partners such as Eli Lilly, Laboratoires Servier, Takeda, SK Biopharmaceuticals, and Qilu Pharmaceutical. The company also nominated nine development candidates within nine months of 2026 and advanced Rentosertib, the world's first generative AI-discovered drug candidate, to a Phase III trial for idiopathic pulmonary fibrosis.

90 Insilico Medicine announced inclusion HKEX Tech 100 Index
80 Insilico Medicine reported revenue
80 Insilico Medicine achieved profitability
70 Insilico Medicine signed collaborations
70 Insilico Medicine advanced drug trial Rentosertib
60 Insilico Medicine nominated candidates
priv
Central company; inclusion enhances visibility, liquidity, and capital access, likely benefiting its stock.
Importance 100.0 Sentiment 80.0
index
Benchmark index; adding Insilico reflects its AI and biotech exposure, potentially increasing index relevance.
Importance 90.0 Sentiment 50.0
exch
Exchange operator; methodology changes and index inclusion support its tech-focused product offerings.
Importance 70.0 Sentiment 40.0
oth
Channel for Mainland investors; inclusion enables inflows into Insilico via this mechanism.
Importance 60.0 Sentiment 50.0
oth
Lead drug candidate; Phase III trial progress highlights Insilico's AI capabilities, supporting positive sentiment.
Importance 40.0 Sentiment 60.0
stock
Collaboration partner; contributes to Insilico's revenue growth, but no direct impact from index inclusion.
Importance 30.0 Sentiment 40.0
priv
Collaboration partner; contributes to Insilico's revenue growth, but no direct impact from index inclusion.
Importance 30.0 Sentiment 40.0
stock
Collaboration partner; contributes to Insilico's revenue growth, but no direct impact from index inclusion.
Importance 30.0 Sentiment 40.0
stock
Collaboration partner; contributes to Insilico's revenue growth, but no direct impact from index inclusion.
Importance 30.0 Sentiment 40.0
priv
Collaboration partner; contributes to Insilico's revenue growth, but no direct impact from index inclusion.
Importance 30.0 Sentiment 40.0
index
Previously included; no direct impact from this event.
Importance 20.0 Sentiment 30.0
index
Previously included; no direct impact from this event.
Importance 20.0 Sentiment 30.0
index
Previously included; no direct impact from this event.
Importance 20.0 Sentiment 30.0
index
Previously included; no direct impact from this event.
Importance 20.0 Sentiment 30.0
index
Previously included; no direct impact from this event.
Importance 20.0 Sentiment 30.0
+ 5 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.